{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:55:00Z","timestamp":1790747700346,"version":"4.1.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose\/Objective(s)<\/jats:title>\n                    <jats:p>Recurrent and metastatic non-anaplastic thyroid cancer has traditionally been considered relatively radioresistant. We evaluated whether anatomic site or histology risk group better predicts local control (LC) following stereotactic radiation therapy (SBRT\/SRS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials\/Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed 32 patients with 66 treated lesions (42 skeletal, 24 non-skeletal) treated between 2012 and 2025. Histology was dichotomized into low-risk (papillary, follicular, medullary, H\u00fcrthle cell; n=61) and high-risk (poorly differentiated and squamous cell carcinoma; n=5). BED\n                      <jats:sub>10<\/jats:sub>\n                      was calculated using \u03b1\/\u03b2 = 10 Gy. LC was defined per RECIST 1.1. Kaplan\u2013Meier and log-rank tests were used. Intra-patient correlation was addressed via generalized estimating equations (GEE) and Cox shared frailty models. A multivariable GEE model included histology risk, site, BED\n                      <jats:sub>10<\/jats:sub>\n                      , PTV volume, prior surgery, and age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median follow-up was 15.0 months. Six local failures occurred (crude LC 90.9%); 1- and 2-year LC were 96.5% and 87.1%. Histology risk was the dominant determinant: low-risk histology achieved 95.1% crude LC versus 40.0% for high-risk (log-rank p=0.002). In multivariable GEE analysis, low-risk histology was independently associated with LC (OR 158.0, 95% CI 1.72\u201314,479.7; p=0.028), whereas skeletal site was not (OR 1.07, 95% CI 0.02\u201351.8; p=0.974). BED\n                      <jats:sub>10<\/jats:sub>\n                      was not associated with LC after adjustment (p=0.752). Skeletal and non-skeletal LC were similar after histology stratification (95.0% vs 95.2% among low-risk). Treatment was well tolerated; no Grade \u22653 radiation toxicity, myelopathy, or fractures occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In stereotactic radiation for metastatic non-anaplastic thyroid cancer, histology risk grouping\u2014not anatomic site or dose escalation\u2014is the dominant predictor of local control. These findings support histology-based risk stratification for SRT patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1898567","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:33Z","timestamp":1790744193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Local control after stereotactic radiation for thyroid cancer: a histology risk-stratified analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Bin","family":"Gui","sequence":"first","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Radiation Medicine","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayavignesh","family":"Sekar","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Radiation Medicine","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Locke","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Medical Oncology","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamali","family":"Saha","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Radiation Medicine","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Tulchinsky","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Radiation Medicine","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Jones","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Radiation Medicine","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagashree","family":"Seetharamu","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Medical Oncology","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Ghaly","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["New Hyde Park, NY, United States"]},{"name":"Department of Radiation Medicine","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3171\/2019.12.SPINE191269","article-title":"Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience","volume":"32","author":"Boyce-Fappiano","year":"2020","journal-title":"J Neurosurg Spine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2009.12.034","article-title":"Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer","volume":"142","author":"Kim","year":"2010","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-022-01489-2","article-title":"Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review","volume":"127","author":"Lancellotta","year":"2022","journal-title":"Radiol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.11.046","article-title":"High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions","volume":"71","author":"Yamada","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.04.019","article-title":"21 years of biologically effective dose","volume":"76","author":"Fowler","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.12.034","article-title":"The linear-quadratic model is inappropriate to model high-dose per fraction effects","volume":"70","author":"Kirkpatrick","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12040866","article-title":"Long-term outcome of differentiated thyroid cancer patients\u2014fifty years of Croatian thyroid disease referral centre experience","volume":"12","author":"Juki\u0107","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30665-4","article-title":"Evolving molecularly targeted therapies for advanced-stage thyroid cancers","volume":"22","author":"Bible","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0227","article-title":"Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E-mutated anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac065","article-title":"Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit","volume":"27","author":"Wirth","year":"2022","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:35Z","timestamp":1790744195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1898567"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1898567","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1898567"}}